Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial.
A randomized, double-blind, placebo-controlled trial of cotreatment with biosynthetic, human sequence, growth hormone (GH), and human menopausal gonadotropins (hMG) for induction of ovulation was performed in 16 women with amenorrhea and anovulatory infertility. Patients were randomly allocated to treatment with hMG + GH (24 IU on alternate days, total dose 144 IU) or hMG + placebo. Those who received placebo were given GH in a subsequent course of treatment. On cotreatment with GH compared with placebo, there was a significant reduction in the required dose of hMG, duration of treatment, and the daily effective dose of gonadotropins. Serum insulin-like growth factor-I (IGF-I) rose during treatment with GH but not with placebo. We conclude that growth hormone augments the response of the human ovary to stimulation by gonadotropins. These results suggest a role for the use of GH in induction of ovulation.
Homburg
R
R
Cobbold Laboratories, University College and Middlesex School of Medicine, Middlesex Hospital, London, United Kingdom.
West
C
C
Torresani
T
T
Jacobs
H S
HS
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D000858:Anovulation / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D007016:Hypophysectomy; D007247:Infertility, Female / Q000188:drug therapy*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D007335:Insulin-Like Growth Factor II / Q000378:metabolism; D008596:Menotropins / Q000627:therapeutic use*; D010062:Ovulation Induction; D010911:Pituitary Neoplasms / Q000601:surgery; D011897:Random Allocation
D008596:Menotropins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone